Am J Health Syst Pharm. 2007;64(12):1265-1273. Vildagliptin has been shown to be relatively safe in clinical trials; however, long-term evaluation of safety data and clinical experience of the ...

Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.